The Chartis® Tablet

Accurately predict responders to Zephyr ® Valve treatment

The Chartis System* has been used in multiple randomized clinical trials1-4 to predict likely responders to the Zephyr Valve treatment. It provides precise flow and pressure readings for specific lobes in the lung to assess absence of collateral ventilation, which is a predictor of response to treatment.

Bluetooth® is a registered trademark owned by Bluetooth SIG, Inc.
*The Chartis System includes the Chartis Console and Catheter.
Chartis

Overview of the Chartis Tablet features:

Chartis

Touchscreen

12.5″ wide viewing angle display. Full HD (1920 x 1080) graphics with “View Anywhere®” outdoor 1000 nit sunlight readable display

Chartis

Viewing Flexibility

The tablet display can be moved or viewed independent of its base, which houses the interface with the Chartis catheter, to maximize utilization of space in the operating room and support simultaneous bronchoscope and Chartis visualization

Chartis

Multiple Ventilation Modes

Works with spontaneous breathing or mechanical ventilation

Chartis

Password Protected Log in and Secure Data Storage

Offers superior protection that can support hospital administration and PHI (protected health information) compliance considerations

Chartis

Bluetooth® Connectivity

Allows the tablet display to be positioned in easy view and reach

In patients who have been assessed by the Chartis System as having low collateral ventilation, treatment with Zephyr Endobronchial Valves lead to high responder rates and clinically significant improvement in symptoms compared to Standard of Care (SOC)1.

High Responder Rate for Patients Receiving Zephyr Valve Therapy1

LIBERATE - MCID - Radar | amCharts

Chartis enables detection of collateral ventilation under different sedation methods

Chartis

Chartis System Ordering Information*

DescriptionCatalog Number
Chartis Pulmonary Assessment System – ConsoleCHR-CO-300
Chartis CatheterCHR-CA-12.0
Chartis

Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.

*Not available in all markets.

Privacy Preference Center